Keywords
How to Cite
Abstract
The inherent challenges in the diagnosis and treatment of Cystic Fibrosis (CF), particularly in pediatric patients, are explored in this article. In the realm of diagnosis, the complexities associated with identifying CF in children are addressed, emphasizing the need for comprehensive and timely assessments. The diagnostic process involves intricate procedures, such as genetic and sweat chloride tests, whose interpretation requires specific considerations of pediatric physiology. Early detection proves crucial given the progressive nature of the disease.
In examining the therapeutic spectrum, the challenges faced in treating pediatric CF patients are scrutinized. Various issues arise, from optimizing nutritional support to administering appropriate medications, incorporating an approach to the psychosocial aspects inherent in managing chronic diseases in children. There is a highlighted need for a holistic perspective that encompasses not only medical interventions but also psychosocial support tailored to the specific demands of this population.
Lastly, the article reflects on the comprehensive challenges inherent in pediatric CF care, emphasizing ongoing developments in research and therapeutic modalities. Persistent efforts to enhance diagnostic accuracy and therapeutic outcomes are underscored. In summary, this analysis highlights the complexity of challenges in the sphere of pediatric Cystic Fibrosis, advocating for a multidisciplinary approach to enhance diagnostic precision and treatment efficacy in this vulnerable population.
References
CONTI, Jessica; SORIO, Claudio; MELOTTI, Paola. Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis. Children, v. 10, n. 4, 2023.
GURSOY, Tugba Ramasli et al. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers. European Journal of Pediatrics, v. 182, p. 1067–1076, 2023.
IMBURGIA, Taylor A.; ENGDAHL, Samantha R.; PETTIT, Rebecca S. Evaluation of the safety of cefepime prolonged infusions in pediatric patients with cystic fibrosis. Pediatric Pulmonology, v. 57, p. 919–925, 2022.
MANZOOR, J.; HUGHES, D.A. Cystic Fibrosis screen positive, inconclusive diagnosis (CFSPID) to Cystic Fibrosis: Detecting disease with serial assessments. Paediatric Respiratory Reviews, v. 47, p. 19–22, 2023.
OCHS, Madeleine A.; DILLMAN, Nicholas O.; CAVERLY, Lindsay J.; CHAFFEE, Valerie D. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, v. 56, p. 3634–3643, 2021.
OLIVIER, Margarete et al. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis. Frontiers in Pharmacology, v. 14, art. 1176815, 2023.
SCHWARZ, Carsten et al. Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosis—A Single-Centre Prospective Observational Study. Antibiotics, v. 12, n. 734, 2023.
STAHL, Mirjam et al. Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society, v. 20, n. 8, 2023.
STEINKE, Eva et al. TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease. Frontiers in Medicine, v. 9, art. 1034290, 2023.
TURAL, Dilber Ademhan et al. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis. Pediatric Pulmonology, v. 57, p. 142–151, 2022.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Júlia Moreno Castro de Oliveira, Wilson Sant Anna Lopes Neto , Mariana Chodaski Perinni , Luiza Tibério Campos Calegário, Paola Miranda da Silva Pimente